New Brunswick, NJ--Natreon announce the grant of a U.S. Patent (US 10,500,240) onTerminalia chebula. This expands the company's patent portfolio to a total of 24 active patents, according to a press release, and the company also has 40 published clinical trials.

The primary claim in the new patent: "a method of treating osteoarthritis in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of a composition comprising a Terminalia chebula extract comprising a hydrolyzable tannoid blend, said blend comprising about 8-25% by weight chebulagic acid based on the total weight of the extract and about 15-30% by weight chebulinic acid based on the total weight of the extract."

The secondary claim: "a method of reducing pain and inflammation in an individual with osteoarthritis in need thereof, comprising orally administering to the individual in need thereof a therapeutically effective amount of a composition comprising a Terminalia chebula extract comprising a hydrolyzable tannoid blend, said blend comprising about 8-25% by weight chebulagic acid based on the total weight of the extract and about 15-30% by weight chebulinic acid based on the total weight of the extract."

Natreon also reported tht the published randomized, double-blind, placebo-controlled clinical study tested 100 subjects with joint discomfort. "Based on the information from which this patent has been issued, the results have shown a significant reduction in WOMAC, KSI, and VAS scores for pain and stiffness."
Related: T. bellerica Reduces Uric Acid in Study Branded Ingredient Relieves Joint Pain in Study Natreon’s Shilajit Shown to Induce Genes Relevant to Skin Health
Bruce Brown, President of Natreon, said in the release, "Natreon is centered on the idea of 'trusted science, naturally' and our investment in clinical research demonstrates our commitment to this ideal. We are excited by the opportunities ahead as the market continues to seek botanical products backed by science."